Alzheimer’s disease affects more than 7 million adults in the United States, and researchers expect that number to double by 2060 as the population ages. Women account for a larger share of these cases and often experience faster cognitive decline than men.

A new study from Mayo Clinic researchers offers a possible explanation for part of that difference. The analysis suggests that a protein typically linked to Parkinson’s disease — called alpha-synuclein — may accelerate Alzheimer’s-related changes in the brain, particularly in women.

The findings were published in JAMA Network Open.

Exploring a Protein Associated With Parkinson’s Disease

Alzheimer’s disease is a progressive neurological condition that gradually impairs memory, reasoning, and the ability to carry out everyday tasks. Although there is no cure, medications such as cholinesterase inhibitors and memantine may help manage symptoms in some patients. Newer therapies targeting early disease stages aim to reduce the buildup of harmful plaques in the brain.

Parkinson’s disease, while distinct, is also a progressive brain disorder. It is primarily known for movement-related symptoms such as tremors, stiffness, and slowed movement. Like Alzheimer’s disease, Parkinson’s involves abnormal protein accumulation in the brain.

In Alzheimer’s disease, a protein called tau builds up in nerve cells and contributes to the disease’s progression. In Parkinson’s disease, abnormal forms of alpha-synuclein accumulate in the brain.

Because both conditions involve abnormal protein deposits, researchers have long suspected that these processes might interact.

Study Design and Participants

To investigate the possible connection, researchers analyzed data from 415 participants enrolled in the Alzheimer’s Disease Neuroimaging Initiative, a large research program designed to track brain changes associated with dementia.

Participants included individuals who were cognitively healthy as well as those with mild cognitive impairment or dementia.

Researchers measured alpha-synuclein and tau levels using:

  • Cerebrospinal fluid testing, which evaluates proteins associated with neurological disease
  • Brain imaging scans, which track changes in brain structure and pathology

The data covered the period from 2015 to 2023, with participants followed for a median period of approximately 1.2 years.

A Stronger Effect Observed in Women

The study found that abnormal alpha-synuclein was detected more frequently in men. About 21.5% of men tested positive for the protein, compared with roughly 12% of women.

However, the biological impact appeared to differ by sex.

Among women who tested positive for abnormal alpha-synuclein, the accumulation of tau — the protein strongly linked to Alzheimer’s progression — occurred dramatically faster. The rate of tau buildup in these women was estimated to be about 20 times higher than in men with similar alpha-synuclein levels.

These results suggest that alpha-synuclein may act as a biological accelerator of Alzheimer’s disease in some women.

The finding could help explain why women represent nearly two-thirds of Alzheimer’s cases in the United States.

Why Sex Differences Matter in Alzheimer’s Research

Researchers emphasize that biological sex may play a larger role in dementia research than previously recognized.

The study’s lead author noted that differences between men and women should be considered carefully when interpreting findings related to dementia progression.

However, the number of women in the study who tested positive for alpha-synuclein was relatively small. Additional research will be needed to confirm whether the observed pattern holds true in larger populations.

Implications for Future Treatments

If future studies confirm these results, they could influence how Alzheimer’s disease is studied and treated.

Scientists are increasingly recognizing that many patients develop mixed brain pathologies, meaning that more than one disease-related protein may be present at the same time.

Understanding how these proteins interact could help guide the development of new therapies that target multiple biological pathways simultaneously.

Experts note that the study does not change current clinical practice. Men and women with Alzheimer’s disease are still treated using the same approaches today.

However, the findings suggest that future treatment strategies may eventually become more personalized, taking into account both biological sex and the presence of additional disease-related proteins.

A Step Toward More Precise Understanding

Researchers say the study represents an important step toward understanding why Alzheimer’s disease progresses differently from person to person.

Rather than simply noting that women appear to be more affected by the disease, the findings point to possible biological mechanisms that may influence how the condition develops.

As Alzheimer’s research advances, identifying these mechanisms may help scientists design more targeted treatments — with the goal of slowing disease progression and improving quality of life for patients and their families.